GLOW
GLOW Stack · GLOW 70 · Triple G · BPC/TB/GHK Blend
Last updated
At a glance
Overview
What GLOW Actually Is#
GLOW is a pre-mixed peptide blend — BPC-157 + TB-500 + GHK-Cu — sold almost exclusively in a 70 mg vial (50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500). Three peptides, three complementary repair pathways, one sub-Q injection per day. It earned its name from the skin-quality transformation looksmaxxers report around week 4–6, but the physique and recovery crowd runs it just as hard for tendon rehab, post-cycle connective-tissue insurance, and accelerated healing after microneedling, PRP, or surgery.
The logic is synergy, not redundancy. BPC-157 drives angiogenesis and tendon/ligament repair through VEGFR2 signaling. TB-500 binds actin and handles cell migration, anti-fibrotic remodeling, and systemic reach into tissues BPC doesn't prioritize. GHK-Cu delivers copper to fibroblasts and triggers collagen, elastin, and glycosaminoglycan synthesis at the dermal level. You're covering vasculature, cellular motility, and matrix synthesis in one shot instead of stacking three separate vials.
"GHK regulates expression of approximately 4,000 human genes, restoring a more youthful pattern of gene expression, stimulating collagen and glycosaminoglycan synthesis, and increasing cellular regenerative capacity." — Pickart & Margolina, Int J Mol Sci (2018)
Why People Run It#
The community splits roughly into two camps. The aesthetics/looksmaxxing crowd uses GLOW primarily for skin tone, elasticity, and post-procedure recovery — it pairs with tretinoin, microneedling, and red-light work in the same way a well-built hair stack pairs finasteride, minoxidil, and a topical antiandrogen. The physique and recovery crowd runs it for tendon and joint rehab (elbow tendinopathy from heavy pressing, patellar issues, rotator cuff), as on-cycle connective-tissue insurance during harsh orals, and as a recovery block between heavy blasts.
It's non-hormonal, runs identically in men and women, requires no PCT, and doesn't move lipids, liver markers, or the HPTA. That's a rare profile — most of the upside with almost none of the systemic cost, provided you respect the one hard contraindication (active or undiagnosed malignancy; all three peptides are pro-angiogenic).
What This Guide Covers#
Below we'll walk through the 70 mg vial reconstitution math (so you know exactly what 10 IU delivers), dose ladders for beginner through advanced use, protocol templates for skin, tendon rehab, on-cycle support, and post-procedure recovery, the stacks that amplify it (CJC/Ipamorelin, daily tadalafil, collagen + vitamin C timing), side effects and the contraindications that actually matter, half-life and PK for each component, and the community sourcing rules that separate a legit 50/10/10 vial from an underdosed knock-off. By the end you'll know what to order, how to draw it, and how to run it for your specific goal.
How GLOW works
GLOW isn't one peptide — it's three, each hitting a different node of the tissue-repair cascade. BPC-157 runs the vascular and tendon-fibroblast side, TB-500 handles cellular migration and anti-fibrotic remodeling, and GHK-Cu drives extracellular matrix synthesis and shuttles copper into cells. The reason the blend got traction isn't marketing — it's that these three peptides cover complementary mechanisms rather than redundantly hitting the same pathway. You get vasculature, cell motility, and matrix rebuild in one shot.
Angiogenesis — BPC-157 Driving New Vasculature#
BPC-157 promotes new capillary formation at injury sites through the VEGFR2–Akt–eNOS axis. Injured tissue that couldn't previously get adequate perfusion suddenly can, which is why tendons — notoriously avascular, notoriously slow to heal — respond to BPC dosing in ways they don't respond to rest alone.
"The pro-angiogenic effect of BPC157 is mediated through the activation and up-regulation of VEGFR2, which drives new blood vessel formation critical for tissue healing." — Hsieh et al., J Mol Med, 2017
Practical payoff: this is why injecting close to the injury site (elbow, knee, shoulder) is the community-preferred approach for rehab work. More capillary density at the damaged tissue means faster delivery of nutrients, oxygen, and — usefully — the other two peptides in the blend.
Actin Sequestration and Cell Migration — TB-500's Core Mechanism#
Thymosin β-4 is the major G-actin-sequestering peptide in mammalian cells. By binding monomeric actin and controlling its polymerization into F-actin filaments, TB-500 enables the cytoskeletal remodeling that lets cells actually move — endothelial cells migrating into wound beds to form new vessels, keratinocytes crawling across a healing dermis, myocytes and satellite cells mobilizing to damaged muscle fibers.
"Thymosin β4 binds actin and promotes cell migration, angiogenesis, and tissue remodeling. It plays a key role in healing via anti-inflammatory and anti-fibrotic actions." — Goldstein et al., Expert Opin Biol Ther, 2012
Two things fall out of this for the reader. First, TB-500's anti-fibrotic signature (NF-κB downregulation, reduced collagen III-to-I scarring ratio) is the reason it's the go-to add for post-procedure recovery — microneedling, laser, surgery — where you want healing without a raised scar. Second, it diffuses systemically in a way BPC doesn't, which is why standalone TB-500 protocols are the move for spinal, cardiac, or CNS-adjacent complaints the blend alone won't fully address.
Fibroblast Activation and Tendon Remodeling#
Tendon healing is the use case that put this stack on the map, and it's BPC-157 doing most of that work. BPC directly increases the outgrowth, migration, and survival of tendon fibroblasts, and it upregulates the growth hormone receptor on those fibroblasts — meaning any endogenous GH pulse (or an exogenous GHRH/GHRP stack like CJC-1295/Ipamorelin) hits harder on healing connective tissue during a GLOW run.
"BPC 157 significantly enhanced the outgrowth of tendon fibroblasts, promoted cell survival, and increased migration, suggesting a potential therapeutic effect on tendon injuries." — Chang et al., J Appl Physiol, 2011
This is why the "GLOW + nightly CJC/Ipa" stack isn't just bro-science — there's a mechanistic rationale for the synergy. The BPC is making tendon tissue more GH-responsive while you're pulsing more GH.
Collagen, Elastin, and Gene-Level Reprogramming — GHK-Cu#
GHK-Cu is the reason the blend is called GLOW. The tripeptide shuttles copper into cells and triggers a cascade of ECM synthesis: type I and III collagen, elastin, decorin, and glycosaminoglycans. It simultaneously modulates the MMP/TIMP balance so you get remodeling rather than pure breakdown, and at a transcriptional level it appears to reset a surprisingly large slice of the genome.
"GHK regulates expression of approximately 4,000 human genes, restoring a more youthful pattern of gene expression, stimulating collagen and glycosaminoglycan synthesis, and increasing cellular regenerative capacity." — Pickart & Margolina, Int J Mol Sci, 2018
Translation for the physique-focused reader: visible skin elasticity, tone, and texture improvements at weeks 4–6 of a run; measurable wound-healing acceleration post-procedure; secondary benefits for hair follicle health (which is why GHK-Cu shows up in serious hair-retention stacks alongside finasteride/minoxidil). The copper also supports SOD activity — endogenous antioxidant defense — which is a useful side benefit during heavy training blocks or harsh oral cycles.
Anti-Inflammatory and Protective Signaling#
All three peptides converge on NF-κB downregulation and inflammation control, which is the shared thread that makes the blend feel systemically "good" rather than just locally effective. BPC-157 adds cytoprotection of the gastric mucosa (genuinely useful during oxandrolone, superdrol, or anadrol runs), TB-500 damps myocardial and general tissue inflammation, and GHK-Cu has independent anti-inflammatory and antioxidant activity via copper-dependent enzymes.
The practical framing: GLOW isn't an anabolic. It doesn't move the scale or the mirror on its own. What it does is accelerate the payoff of the work you're already doing — rehab loading, training stress, post-procedure healing, on-cycle recovery — by hitting vascular, cellular, and matrix repair simultaneously. That's the case for running it, and that's why it's earned its spot in the serious recovery and aesthetics stacks.
Protocol
GLOW contains 3 peptides.
| Peptide | Dose / administration | Frequency | Half-Life | Vial |
|---|---|---|---|---|
BPC-157 BPC-157 is a pentadecapeptide that accelerates tissue healing primarily by stimulating angiogenesis via the VEGFR2–Akt–eNOS pathway and upregulating growth hormone receptor express... | 250–1000 mcg | Once daily | 30 minutes | 10 mg |
GHK-Cu GHK-Cu is a tripeptide-copper complex with potent regenerative activity. It upregulates type I/III collagen, elastin, glycosaminoglycan synthesis, and modulates MMPs and TIMPs, dri... | 1250–5000 mcg | Once daily | 10–15 minutes | 50 mg |
TB-500 (Thymosin Beta-4 fragment) TB-500, a synthetic peptide fragment of Thymosin Beta-4, is crucial for cell migration, cytoskeletal dynamics, and anti-fibrotic activity. Its primary mechanism is through actin se... | 250–1000 mcg | Once daily | 2 hours | 10 mg |
Reconstituting a blend vial? Use the peptide calculator → — add one entry per peptide above with its vial mg and dose.
Cycle length & outcomes
Documented cycle
4–12 weeks
Plateau after
12 wks
Cycle Length & Protocol#
GLOW doesn't require loading phases, tapering, or PCT. It's a non-hormonal stack — you start at your target dose on day one and stop when the cycle ends. The only real variable is how long to run and how hard to dose, and both are driven by the goal.
GLOW Cycle Length by Goal#
| Goal | Cycle Length | Daily Dose (from 70mg/2mL vial) | Frequency |
|---|---|---|---|
| Skin quality / aesthetics | 8–12 weeks | 10–20 IU (0.10–0.20 mL) | M–F |
| Tendon / ligament rehab | 6–8 weeks | 20–30 IU (0.20–0.30 mL) | Daily, split AM/PM at >20 IU |
| Post-procedure recovery (micro-needling, PRP, laser, surgery) | 2–4 weeks | 15–20 IU (0.15–0.20 mL) | Daily |
| On-cycle protection during harsh orals | Duration of oral + 2 weeks | 10 IU (0.10 mL) | Daily |
| Recovery block between training phases | 4–6 weeks | 10–15 IU (0.10–0.15 mL) | M–F |
| First-time run / sensitivity check | 4 weeks | 5–10 IU (0.05–0.10 mL) | M–F |
Every 10 IU (0.10 mL) from a properly reconstituted 70mg vial delivers 2.5mg GHK-Cu + 0.5mg BPC-157 + 0.5mg TB-500.
"Every 10 units (0.10 mL) contains 2.5 mg GHK-Cu, 0.5 mg BPC-157, and 0.5 mg TB-500. Most users run 10–20 IU per day, M–F, for 4–8 weeks depending on goal and experience." — r/Peptidesource, GLOW 70 visual dosing guide (2024)
Onset Timing#
Expect a staggered rollout of effects — the three peptides work on different timelines:
- Week 1–2: Injection-site tolerance settles. Some users report transient fatigue from the TB-500 component in the first few days; this passes.
- Week 2–3: First noticeable changes in soft-tissue pain, joint feel, and minor skin texture (hydration, tone). BPC-157's angiogenic signaling is active early.
- Week 4–6: The collagen/ECM remodeling from GHK-Cu starts showing visibly — skin elasticity, pore refinement, scar softening. Tendon pain scores drop meaningfully in rehab protocols.
- Week 6–8+: Peak remodeling. This is where longer cycles pay off — you're banking the cumulative GHK-driven transcriptional shift.
"GHK regulates expression of approximately 4,000 human genes, restoring a more youthful pattern of gene expression, stimulating collagen and glycosaminoglycan synthesis, and increasing cellular regenerative capacity." — Pickart L, Margolina A., Int J Mol Sci (2018)
Tapering & Loading#
There is no taper and no loading phase. Unlike TB-500 as a standalone (where a front-load of 5–10mg in week 1 is common), the GLOW blend's fixed ratio means loading the TB component also loads the GHK-Cu — and stacking GHK-Cu heavy early is pointless since its effects are driven by sustained tissue exposure, not peak plasma levels.
If you're rehabbing a serious tear and want to front-load the TB-500 axis specifically, the community solution is to run standalone TB-500 at 2.5mg twice weekly for the first 2 weeks on top of your GLOW protocol, then drop back to GLOW alone. Don't try to replicate this by doubling your GLOW dose — you'll overdose the copper.
On-Cycle Bloodwork#
GLOW doesn't move androgens, lipids, liver enzymes, or hematocrit in any meaningful way, so routine on-cycle labs aren't required for safety. Reasonable cadence:
- Baseline CBC + CMP before a first run
- Retest at 8–12 weeks if cycling continuously beyond that
- Serum copper + ceruloplasmin if running GLOW continuously past 6 months (rare but worth checking given the GHK-Cu load)
The real monitoring is visual and functional: photograph skin monthly under the same lighting for aesthetic runs, track pain scores and ROM for rehab runs.
Cycle Frequency#
Most experienced users run 2–3 GLOW cycles per year — typically timed to injury events, post-procedure recovery windows, or aesthetic goals (pre-summer, pre-event). The M–F dosing pattern with weekends off is the dominant community standard and preserves peptide sensitivity without any real evidence of tolerance even on 7-day protocols. Off-cycles of 4 weeks between runs are sufficient.
For chronic joint issues, running a 6-week GLOW block once per training quarter is a defensible long-term strategy — you get cumulative ECM benefits without committing to indefinite injection.
Risks & mistakes
Common (most users)#
- Injection-site reactions — redness, itch, small welts, transient bruising. GHK-Cu is the most likely culprit for a histamine-like flush. Rotate sites (abdomen, flank, upper thigh), inject slowly with a fresh 31 G ½" pin, and let the solution warm to room temp before drawing. If one site keeps flaring, move to the opposite flank for a week.
- Transient fatigue / lethargy in week 1–2 — commonly reported with the TB-500 component as tissue remodeling ramps up. Usually resolves by the end of week 2. If it's bothersome, shift the shot to evening and let the grogginess run into sleep.
- Mild flushing or lightheadedness post-injection — consistent with the angiogenic / vasodilatory action of BPC-157 and TB-500 (Hsieh et al., 2017). Hydrate, dose with food, and sit down for 10 minutes after the shot if you're prone to it.
- Mild headache or appetite shift — scattered reports, dose-dependent. Drop back one tier for a week and re-titrate.
- Metallic taste — occasional with GHK-Cu from copper delivery. Harmless, fades in hours. If persistent, back the dose off to the beginner tier.
"GHK regulates expression of approximately 4,000 human genes, restoring a more youthful pattern of gene expression, stimulating collagen and glycosaminoglycan synthesis, and increasing cellular regenerative capacity." — Pickart & Margolina, Int J Mol Sci (2018)
Uncommon (dose-dependent or individual)#
- Persistent injection-site welts or urticaria — more common at advanced-tier doses (20–30 IU daily) or when dosing into the same site repeatedly. Rotate aggressively, split AM/PM, and consider dropping the daily volume by 25% for a week.
- Prolonged fatigue past week 2 — if the TB-500-flavored lethargy hasn't cleared, drop to M–W–F dosing or pull back to 10 IU until it resolves.
- Mood / sleep shifts — occasional reports of vivid dreams or light sleep disturbance. Shift dosing to morning.
- Elevated serum copper on extended runs — theoretical but worth checking on cycles longer than 12 weeks or back-to-back blocks. Pull serum copper + ceruloplasmin at the 8–12 week mark if you're running GLOW continuously.
- Nevus / mole changes — any new pigmentation, darkening, or growth of existing lesions during a run is a stop-and-screen signal, not a "watch and see" signal. See below.
| Check | When | Why |
|---|---|---|
| CBC / CMP | Baseline + 8–12 weeks on extended cycles | General safety; liver/kidney are unaffected but worth a baseline |
| Serum copper + ceruloplasmin | At 12 weeks if running continuously | GHK-Cu delivers copper; relevant only on long runs |
| Full-body skin check | Before first cycle if any family history or atypical moles | Non-negotiable given the angiogenic profile |
Rare but serious#
- Accelerated growth of an undiagnosed lesion — all three peptides are pro-angiogenic and promote cellular proliferation, and Tβ4 has been implicated in tumor cell migration in some in-vitro models (Goldstein et al., 2012). Any rapidly changing mole, lump, or lesion during a cycle = stop immediately and get it screened. Don't "finish the vial and see."
- Severe hypersensitivity / systemic allergic reaction — rare, but blended peptide products carry more antigen surface than single-peptide vials. Hives beyond the injection site, facial swelling, or breathing changes mean stop and seek care.
- Injection-site infection / abscess — sterile technique failure, not a peptide problem. Warm, spreading redness with fever is not an "irritation" — it's a clinic visit.
- Unexplained bleeding or clotting changes — Tβ4 influences endothelial and platelet dynamics; the signal is weak but if you're on anticoagulants and see bruising patterns shift, stop and reassess.
Hard contraindications#
- Active malignancy or any undiagnosed lesion / lump / skin change. Non-negotiable. BPC-157 drives VEGFR2-mediated angiogenesis; TB-500 drives cell migration; GHK-Cu drives proliferation. You do not feed a tumor with this stack. Get screened clean first.
- Wilson's disease or known copper hypersensitivity. GHK-Cu delivers copper by design. Disqualifying.
- Pregnancy, lactation, or active attempts to conceive (for female users). No human reproductive data on any of the three components. Don't.
- Active infection at the intended injection site. Treat the infection first; angiogenic peptides into infected tissue is a bad trade.
- Post-transplant or pharmacologically immunosuppressed state. TB-500's NF-κB modulation and chemotactic effects are unpredictable in this population — talk to the transplant team before running anything like this.
- Recent (< 6 months) history of melanoma or other skin malignancy. Same angiogenesis logic as active malignancy. Wait for clear surveillance.
Gender, fertility, and PCT#
GLOW is fully non-hormonal — no HPTA suppression, no aromatization, no AR binding, no SHBG impact. It runs identically in men and women and is one of the few injectables that can sit alongside a pregnancy-planning window for the male partner without concern (no semen-quality signal in the literature). No PCT required, and no PCT interference — GLOW can be run during PCT as a recovery adjunct if you're coming off a hard blast and want connective-tissue support while test recovers. Women get the same skin, tendon, and recovery benefits at the same dose tiers; no virilization axis to worry about.
Stack & combine
Multipliers applied when these compounds run together. Values > 1 indicate a bonus on that axis. Tap a partner to expand the mechanism.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| synergistic | ×1.15 | ×1.22 | ×1.25 | |
| synergistic | ×1.00 | ×1.00 | ×1.18 | |
| synergistic | ×1.00 | ×1.00 | ×1.18 | |
| synergistic | ×1.00 | ×1.00 | ×1.18 | |
| synergistic | ×1.00 | ×1.00 | ×1.18 |
FAQ — GLOW
Where to buy
Research & citations
5 studies cited on this page.
Conclusion
GLOW is a high-yield healing blend for users targeting faster tendon repair, anti-fibrotic recovery, and visible skin upgrades — all in a single daily sub-Q shot.
Key takeaways:
- Standard dose: 10–20 IU (0.10–0.20 mL) sub-Q daily, M–F (2.5–5 mg GHK-Cu / 0.5–1 mg BPC / 0.5–1 mg TB)
- Cycle: 6–8 weeks on, 4 weeks off is the most common protocol
- Inject near the injury for tendon/ligament rehab; rotate sites for skin and aesthetics use
- Stack with daily tadalafil (5 mg) for blood flow or CJC-1295/Ipamorelin for GH synergy
- No PCT, no AR suppression — safe for men and women (outside listed contraindications)
- Major benefit: maximized tissue regeneration (angiogenesis, collagen, cell migration) with minimal systemic sides
If you're serious about healing connective tissue fast, boosting post-procedure skin results, or just want high-impact recovery support, GLOW is one of the most effective and user-friendly blends on the market.